The Parasym Device​ Significantly Increases Parasympathetic Activity​

Parasym Clinical Trial, 2022

 

This study included 20 healthy participants. Participants abstained from caffeine, exercise, smoke, and alcohol in the 5 hours preceding the experiment and were blinded to active or sham treatment.

 

Autonomic function measured by HRV components was significantly affected in the active group (n=10) receiving Parasym neuromodulation compared to the placebo group (n=10) receiving placebo neuromodulation. After 5 minutes of neuromodulation the following HRV components were positively altered in the active group receiving Parasym neuromodulation compared to the placebo group:

 

(A) HF (High-Frequency Power)

(B) RMSSD (Root Mean Square of Successive Differences)

(C) pRR50 (Percentage of Successive RR Intervals > 50 ms Difference)

(D) SDRR (Standard Deviation of RR Intervals)

 

Changes HF, RMSSD, pRR50, and SDRR compared to baseline persisted in the active group during the recovery phase, 5 minutes after the neuromodulation was interrupted. No adverse effects were observed by any of the participants.

 

 

Parasym Clinical Trial, 2022

 

This study included 20 healthy participants. Participants abstained from caffeine, exercise, smoke, and alcohol in the 5 hours preceding the experiment and were blinded to active or sham treatment.

 

Autonomic function measured by HRV components was significantly affected in the active group (n=10) receiving Parasym neuromodulation compared to the placebo group (n=10) receiving placebo neuromodulation. After 5 minutes of neuromodulation the following HRV components were positively altered in the active group receiving Parasym neuromodulation compared to the placebo group:

 

(A) HF (High-Frequency Power)

(B) RMSSD (Root Mean Square of Successive Differences)

(C) pRR50 (Percentage of Successive RR Intervals > 50 ms Difference)

(D) SDRR (Standard Deviation of RR Intervals)

 

Changes HF, RMSSD, pRR50, and SDRR compared to baseline persisted in the active group during the recovery phase, 5 minutes after the neuromodulation was interrupted. No adverse effects were observed by any of the participants.